Literature DB >> 21888621

Efficacy and safety of Sleeping Beauty transposon-mediated gene transfer in preclinical animal studies.

Perry B Hackett1, Elena L Aronovich, David Hunter, Myra Urness, Jason B Bell, Steven J Kass, Laurence J N Cooper, Scott McIvor.   

Abstract

Sleeping Beauty (SB) transposons have been effective in delivering therapeutic genes to treat certain diseases in mice. Hydrodynamic gene delivery of integrating transposons to 5-20% of the hepatocytes in a mouse results in persistent elevated expression of the therapeutic polypeptides that can be secreted into the blood for activity throughout the animal. An alternative route of delivery is ex vivo transformation with SB transposons of hematopoietic cells, which then can be reintroduced into the animal for treatment of cancer. We discuss issues associated with the scale-up of hydrodynamic delivery to the liver of larger animals as well as ex vivo delivery. Based on our and others' experience with inefficient delivery to larger animals, we hypothesize that impulse, rather than pressure, is a critical determinant of the effectiveness of hydrodynamic delivery. Accordingly, we propose some alterations in delivery strategies that may yield efficacious levels of gene delivery in dogs and swine that will be applicable to humans. To ready hydrodynamic delivery for human application we address a second issue facing transposons used for gene delivery regarding their potential to "re-hop" from one site to another and thereby destabilize the genome. The ability to correct genetic diseases through the infusion of DNA plasmids remains an appealing goal.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21888621      PMCID: PMC3728161          DOI: 10.2174/156652311797415827

Source DB:  PubMed          Journal:  Curr Gene Ther        ISSN: 1566-5232            Impact factor:   4.391


  111 in total

1.  Development of hyperactive sleeping beauty transposon vectors by mutational analysis.

Authors:  Hatem Zayed; Zsuzsanna Izsvák; Oliver Walisko; Zoltán Ivics
Journal:  Mol Ther       Date:  2004-02       Impact factor: 11.454

2.  Hydrodynamics-based procedure involves transient hyperpermeability in the hepatic cellular membrane: implication of a nonspecific process in efficient intracellular gene delivery.

Authors:  Naoki Kobayashi; Makiya Nishikawa; Kazuhiro Hirata; Yoshinobu Takakura
Journal:  J Gene Med       Date:  2004-05       Impact factor: 4.565

Review 3.  Hydrodynamic delivery of DNA.

Authors:  Bradley L Hodges; Ronald K Scheule
Journal:  Expert Opin Biol Ther       Date:  2003-09       Impact factor: 4.388

4.  Gene transfer into genomes of human cells by the sleeping beauty transposon system.

Authors:  Aron M Geurts; Ying Yang; Karl J Clark; Geyi Liu; Zongbin Cui; Adam J Dupuy; Jason B Bell; David A Largaespada; Perry B Hackett
Journal:  Mol Ther       Date:  2003-07       Impact factor: 11.454

5.  Integration and long-term expression in xenografted human glioblastoma cells using a plasmid-based transposon system.

Authors:  John R Ohlfest; Paul D Lobitz; Scott G Perkinson; David A Largaespada
Journal:  Mol Ther       Date:  2004-08       Impact factor: 11.454

6.  Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer.

Authors:  Steven E Raper; Narendra Chirmule; Frank S Lee; Nelson A Wivel; Adam Bagg; Guang-ping Gao; James M Wilson; Mark L Batshaw
Journal:  Mol Genet Metab       Date:  2003 Sep-Oct       Impact factor: 4.797

7.  AAV serotype 2 vectors preferentially integrate into active genes in mice.

Authors:  Hiroyuki Nakai; Eugenio Montini; Sally Fuess; Theresa A Storm; Markus Grompe; Mark A Kay
Journal:  Nat Genet       Date:  2003-07       Impact factor: 38.330

8.  Minicircle DNA vectors devoid of bacterial DNA result in persistent and high-level transgene expression in vivo.

Authors:  Zhi-Ying Chen; Cheng-Yi He; Anja Ehrhardt; Mark A Kay
Journal:  Mol Ther       Date:  2003-09       Impact factor: 11.454

9.  Sustainable correction of junctional epidermolysis bullosa via transposon-mediated nonviral gene transfer.

Authors:  S Ortiz-Urda; Q Lin; S R Yant; D Keene; M A Kay; P A Khavari
Journal:  Gene Ther       Date:  2003-07       Impact factor: 5.250

10.  Long-term transgene expression from plasmid DNA gene therapy vectors is negatively affected by CpG dinucleotides.

Authors:  Bradley L Hodges; Kristin M Taylor; Macy F Joseph; Sarah A Bourgeois; Ronald K Scheule
Journal:  Mol Ther       Date:  2004-08       Impact factor: 11.454

View more
  29 in total

Review 1.  The Sleeping Beauty transposon system: a non-viral vector for gene therapy.

Authors:  Elena L Aronovich; R Scott McIvor; Perry B Hackett
Journal:  Hum Mol Genet       Date:  2011-04-01       Impact factor: 6.150

Review 2.  Manufacture of T cells using the Sleeping Beauty system to enforce expression of a CD19-specific chimeric antigen receptor.

Authors:  H Singh; J S E Moyes; M H Huls; L J N Cooper
Journal:  Cancer Gene Ther       Date:  2015-01-16       Impact factor: 5.987

3.  Transgene Expression in Dogs After Liver-Directed Hydrodynamic Delivery of Sleeping Beauty Transposons Using Balloon Catheters.

Authors:  Kendra A Hyland; Elena L Aronovich; Erik R Olson; Jason B Bell; Myra Urness Rusten; Roland Gunther; David W Hunter; Perry B Hackett; R Scott McIvor
Journal:  Hum Gene Ther       Date:  2017-04-19       Impact factor: 5.695

4.  Rational design for enhanced gene therapy with DNA transposons.

Authors:  Perry B Hackett; Elena L Aronovich
Journal:  Mol Ther       Date:  2014-09       Impact factor: 11.454

5.  Prolonged Expression of Secreted Enzymes in Dogs After Liver-Directed Delivery of Sleeping Beauty Transposons: Implications for Non-Viral Gene Therapy of Systemic Disease.

Authors:  Elena L Aronovich; Kendra A Hyland; Bryan C Hall; Jason B Bell; Erik R Olson; Myra Urness Rusten; David W Hunter; N Matthew Ellinwood; R Scott McIvor; Perry B Hackett
Journal:  Hum Gene Ther       Date:  2017-05-19       Impact factor: 5.695

Review 6.  Lysosomal storage disease: gene therapy on both sides of the blood-brain barrier.

Authors:  Elena L Aronovich; Perry B Hackett
Journal:  Mol Genet Metab       Date:  2014-10-07       Impact factor: 4.797

Review 7.  A new approach to gene therapy using Sleeping Beauty to genetically modify clinical-grade T cells to target CD19.

Authors:  Harjeet Singh; Helen Huls; Partow Kebriaei; Laurence J N Cooper
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

Review 8.  State-of-the-art human gene therapy: part I. Gene delivery technologies.

Authors:  Dan Wang; Guangping Gao
Journal:  Discov Med       Date:  2014 Jul-Aug       Impact factor: 2.970

Review 9.  Engineered T cells for cancer treatment.

Authors:  Usanarat Anurathapan; Ann M Leen; Malcolm K Brenner; Juan F Vera
Journal:  Cytotherapy       Date:  2013-11-13       Impact factor: 5.414

10.  Stable, Nonviral Expression of Mutated Tumor Neoantigen-specific T-cell Receptors Using the Sleeping Beauty Transposon/Transposase System.

Authors:  Drew C Deniger; Anna Pasetto; Eric Tran; Maria R Parkhurst; Cyrille J Cohen; Paul F Robbins; Laurence Jn Cooper; Steven A Rosenberg
Journal:  Mol Ther       Date:  2016-03-05       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.